Cash from Financing (Quarterly) Chart

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2018. Start Trial.
Date Value
September 30, 2026 0.012M
June 30, 2026 0.217M
March 31, 2026 -0.185M
December 31, 2025 -0.196M
September 30, 2025 0.134M
June 30, 2025 -0.116M
March 31, 2025 0.032M
December 31, 2024 0.291M
September 30, 2024 -0.252M
June 30, 2024 21.38M
March 31, 2024 4.13M
December 31, 2023 -0.046M
September 30, 2023 71.93M
June 30, 2023 0.00
March 31, 2023 0.051M
December 31, 2022 -0.028M
Date Value
September 30, 2022 0.052M
June 30, 2022 0.00
March 31, 2022 0.153M
December 31, 2021 0.00
September 30, 2021 0.064M
June 30, 2021 0.184M
March 31, 2021 0.481M
December 31, 2020 0.83M
September 30, 2020 0.27M
June 30, 2020 0.00
March 31, 2020 213.84M
December 31, 2019 83.50M
September 30, 2019 44.33M
June 30, 2019 -0.07M
March 31, 2019 0.00
December 31, 2018 47.32M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Lineage Cell Therapeutics, Inc. -0.023M
Armata Pharmaceuticals, Inc. -0.028M
Voyager Therapeutics, Inc. 3.033M
Invivyd, Inc. 0.028M
Elicio Therapeutics, Inc. 17.78M